What is the 13F Pro Quality Score for RNA?

13F Pro ranks Avidity Biosciences, Inc. (RNA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RNA's current score at https://13fpro.ai/company/RNA (free sign-up required for the full ranking).

Which hedge funds own the most RNA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of RNA include Sessa Capital IM, L.P., PRICE T ROWE ASSOCIATES /MD/, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/RNA as soon as new 13F filings post.

Where does 13F Pro source RNA data?

All Avidity Biosciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. Avidity Biosciences, Inc. files with the SEC under CIK 1599901. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RNA in?

Avidity Biosciences, Inc. (RNA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RNA research updated on 13F Pro?

RNA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Avidity Biosciences, Inc.(RNA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1599901 RNA stock profile & AI dashboard →

13F Pro Quality Score

25.2/100

Rank #2,670 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why RNA.R1599901 Scores 25/100

exact factor attribution · 2026-09-11

RNA.R1599901's composite is driven by revenue growth, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.1 pts

96th pct

Institutional flow

-2.0 pts

10th pct

Earnings growth

-2.2 pts

5th pct

Shareholder dilution

-2.4 pts

3th pct

Earnings quality

-3.5 pts

15th pct

Capital efficiency

-4.5 pts

5th pct

Scale

-5.4 pts

14th pct

Profitability

-6.8 pts

4th pct

Free cash flow

-7.0 pts

3th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

RNA Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Avidity Biosciences, Inc. (RNA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RNA at 25.2/100 on a 32-signal composite quality model, placing it at rank #2,670 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Avidity Biosciences, Inc. reports quarterly revenue of $3.0M, net income of $-20.2M, free cash flow of $-4.0M. Top institutional holders of RNA by reported 13-F value include Sessa Capital IM, L.P., PRICE T ROWE ASSOCIATES, BlackRock, based on the most recent SEC filings. RNA trades on the Nasdaq exchange and files with the SEC under CIK 1599901. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RNA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Avidity Biosciences, Inc. directly from SEC EDGAR.

Revenue

Q2 2026

$3.0M

Net Income

Q2 2026

$-20.2M

Free Cash Flow

Q2 2026

$-4.0M

ROIC

Q2 2026

-42.2%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+72.1% YoY

$18.8MFY 2025

FY22 $9.2MFY23 $9.6MFY24 $10.9MFY25 $18.8M

Net Income

-112.4% YoY

$-684.6MFY 2025

FY22 $-174.0MFY23 $-212.2MFY24 $-322.3MFY25 $-684.6M

Operating Income

-96.9% YoY

$-745.9MFY 2025

FY22 $-178.9MFY23 $-235.6MFY24 $-378.9MFY25 $-745.9M

EPS (Diluted)

-72.0% YoY

$-4.97FY 2025

FY22 $-3.34FY23 $-2.91FY24 $-2.89FY25 $-4.97

Total Assets

-99.5% YoY

$8.4MFY 2025

FY22 $638.8MFY23 $628.6MFY24 $1.56BFY25 $8.4M

Op. Cash Flow

-116.2% YoY

$-650.4MFY 2025

FY22 $-136.3MFY23 $-119.1MFY24 $-300.9MFY25 $-650.4M

Free Cash Flow

-115.6% YoY

$-663.8MFY 2025

FY22 $-139.1MFY23 $-123.3MFY24 $-307.9MFY25 $-663.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$18.8M +72.1%	$10.9M +14.0%	$9.6M +3.6%	$9.2M -1.1%	$9.3M +37.4%	$6.8M
Net Income	$-684.6M -112.4%	$-322.3M -51.9%	$-212.2M -22.0%	$-174.0M -47.4%	$-118.0M -166.1%	$-44.4M
Operating Income	$-745.9M -96.9%	$-378.9M -60.8%	$-235.6M -31.7%	$-178.9M -51.6%	$-118.1M -166.6%	$-44.3M
EPS (Diluted)	$-4.97 -72.0%	$-2.89 +0.7%	$-2.91 +12.9%	$-3.34 -17.2%	$-2.85 -39.0%	$-2.05
Total Assets	$8.4M -99.5%	$1.56B +148.8%	$628.6M -1.6%	$638.8M +49.4%	$427.6M +28.1%	$333.9M
Operating Cash Flow	$-650.4M -116.2%	$-300.9M -152.7%	$-119.1M +12.6%	$-136.3M -43.7%	$-94.8M -155.4%	$-37.1M
Free Cash Flow	$-663.8M -115.6%	$-307.9M -149.8%	$-123.3M +11.4%	$-139.1M -41.1%	$-98.6M -157.9%	$-38.2M

Get alerted when RNA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Avidity Biosciences, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RNA

Sessa Capital IM, L.P.
$20.2M1,500,000 sh
PRICE T ROWE ASSOCIATES INC /MD/
$19.8M1,472,984 sh
BlackRock, Inc.
$19.5M1,447,476 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$11.3M840,600 sh
VANGUARD CAPITAL MANAGEMENT LLC
$9.8M730,831 sh
CRCM LP
$7.8M583,255 sh
TIG Advisors, LLC
$7.6M561,533 sh
GEODE CAPITAL MANAGEMENT, LLC
$5.2M386,929 sh
TWO SIGMA INVESTMENTS, LP
$4.6M345,481 sh
GOLDMAN SACHS GROUP INC
$4.2M310,341 sh

Fund	Value	Shares
Sessa Capital IM, L.P.	$20.2M	1,500,000
PRICE T ROWE ASSOCIATES INC /MD/	$19.8M	1,472,984
BlackRock, Inc.	$19.5M	1,447,476
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$11.3M	840,600
VANGUARD CAPITAL MANAGEMENT LLC	$9.8M	730,831
CRCM LP	$7.8M	583,255
TIG Advisors, LLC	$7.6M	561,533
GEODE CAPITAL MANAGEMENT, LLC	$5.2M	386,929
TWO SIGMA INVESTMENTS, LP	$4.6M	345,481
GOLDMAN SACHS GROUP INC	$4.2M	310,341

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RNA on your watchlist

Track score changes the day Avidity Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RNA a good stock to buy?

13F Pro's AI-powered analysis of Avidity Biosciences, Inc. (RNA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RNA are available on the RNA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. RNA is classified as a small company.

Which hedge funds own RNA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RNA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Avidity Biosciences, Inc.'s investment landscape.